FDA Approvals
On December 5, 2023, the US Food and Drug Administration (FDA) approved FABHALTA® (iptacopan) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).1,2
Learn More
On February 13, 2024, the Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma.
Learn More
On February 15, 2024, the Food and Drug Administration granted traditional approval to tepotinib (Tepmetko, EMD Serono, Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Learn More
On February 16, 2024, the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Learn More
Treatment for Adult Patients With Locally Advanced or Metastatic Urothelial Cancer KEYTRUDA® (pembrolizumab) Injection 100 mg, in combination with enfortumab vedotin, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
Learn More
National Guideline Updates
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Non-Small Cell Lung Cancer to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer v1.2024.
Learn More
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) for Acute Myeloid Leukemia. These NCCN Guidelines® are currently available as Version 1.2024.
Learn More
Coding and Reimbursement Updates
View the February E-Reimbursement Newsletter.
Learn More
Other
View the ASCO in Action February newsletter.
Learn More
ImmunoGen, Inc. is now part of AbbVie, Inc. The acquisition of ImmunoGen is a transformative move for AbbVie and advances the AbbVie mission to make a remarkable impact on patients’ lives and enhance our value as a long-term partner to those who share our vision for solving serious health issues.
Learn More
On behalf of Merck, read more about the update regarding TICE® BCG BCG LIVE (for intravesical use) (“TICE BCG”).
Learn More
